Association of Metformin Use with Osteoarthritis Incidence, Progression, and Joint Arthroplasty Risk in the Knee and Hip: A Systematic Review and Meta-Analysis.

IF 3.8 2区 医学 Q1 ORTHOPEDICS
Kexin Yao, Feng Li, Qiuyuan Wang, Jiayi Guo, Chen Yue, Yapeng Li
{"title":"Association of Metformin Use with Osteoarthritis Incidence, Progression, and Joint Arthroplasty Risk in the Knee and Hip: A Systematic Review and Meta-Analysis.","authors":"Kexin Yao, Feng Li, Qiuyuan Wang, Jiayi Guo, Chen Yue, Yapeng Li","doi":"10.1016/j.arth.2025.09.050","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although hip and knee osteoarthritis (OA) constitutes a major cause of disability globally, disease-modifying therapies do not exist. Preclinical evidence suggests that metformin has disease-modifying potential, but clinical evidence is conflicting. This meta-analysis assessed the effect of metformin on 1) hip/knee OA incidence, 2) radiographic/symptomatic progression, and 3) joint arthroplasty (JA) risk.</p><p><strong>Methods: </strong>We systematically searched the PubMed, Web of Science, Embase, and Cochrane Library databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Random-effects meta-analyses and qualitative synthesis were performed for the prespecified outcomes.</p><p><strong>Results: </strong>Evidence from 13 studies enrolling 167,107 cases demonstrated that metformin users had a 33% lower hip/knee OA incidence (pooled risk ratios (RRs) 0.67, 95% confidence intervals (CI) 0.61 to 0.74). Qualitative synthesis indicated reduced magnetic resonance imaging-assessed medial cartilage loss and delayed symptomatic progression with respect to pain, joint function, and quality of life among metformin users. Crucially, metformin was associated with a 43% lower JA risk (pooled RR 0.57, 95% CI: 0.38 to 0.84), with enhanced protection in those who had pre-existing OA versus those who had diabetes/obesity alone (RR 0.37 versus 0.81) and those receiving more than two years versus two years or less of treatment (RR 0.38 versus 0.80).</p><p><strong>Conclusion: </strong>Metformin may reduce hip/knee OA incidence and slow radiographic/symptomatic progression. It significantly reduces the risk of JA, particularly in patients who have pre-existing OA and receive prolonged metformin therapy. These findings support considering metformin in this subgroup while highlighting the need for trials to confirm its efficacy among patients who have diabetes/obesity, but do not have established OA.</p>","PeriodicalId":51077,"journal":{"name":"Journal of Arthroplasty","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arthroplasty","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.arth.2025.09.050","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Although hip and knee osteoarthritis (OA) constitutes a major cause of disability globally, disease-modifying therapies do not exist. Preclinical evidence suggests that metformin has disease-modifying potential, but clinical evidence is conflicting. This meta-analysis assessed the effect of metformin on 1) hip/knee OA incidence, 2) radiographic/symptomatic progression, and 3) joint arthroplasty (JA) risk.

Methods: We systematically searched the PubMed, Web of Science, Embase, and Cochrane Library databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Random-effects meta-analyses and qualitative synthesis were performed for the prespecified outcomes.

Results: Evidence from 13 studies enrolling 167,107 cases demonstrated that metformin users had a 33% lower hip/knee OA incidence (pooled risk ratios (RRs) 0.67, 95% confidence intervals (CI) 0.61 to 0.74). Qualitative synthesis indicated reduced magnetic resonance imaging-assessed medial cartilage loss and delayed symptomatic progression with respect to pain, joint function, and quality of life among metformin users. Crucially, metformin was associated with a 43% lower JA risk (pooled RR 0.57, 95% CI: 0.38 to 0.84), with enhanced protection in those who had pre-existing OA versus those who had diabetes/obesity alone (RR 0.37 versus 0.81) and those receiving more than two years versus two years or less of treatment (RR 0.38 versus 0.80).

Conclusion: Metformin may reduce hip/knee OA incidence and slow radiographic/symptomatic progression. It significantly reduces the risk of JA, particularly in patients who have pre-existing OA and receive prolonged metformin therapy. These findings support considering metformin in this subgroup while highlighting the need for trials to confirm its efficacy among patients who have diabetes/obesity, but do not have established OA.

二甲双胍使用与膝关节和髋关节骨关节炎发病率、进展和关节置换术风险的关系:一项系统综述和荟萃分析。
背景:尽管髋关节和膝关节骨性关节炎(OA)是全球致残的主要原因,但目前尚不存在改善疾病的治疗方法。临床前证据表明二甲双胍具有改善疾病的潜力,但临床证据是相互矛盾的。本荟萃分析评估了二甲双胍对以下方面的影响:1)髋关节/膝关节OA发生率,2)影像学/症状进展,以及3)关节置换术(JA)风险。方法:我们系统地检索PubMed、Web of Science、Embase和Cochrane图书馆数据库,遵循系统评价和meta分析指南的首选报告项目。对预先指定的结果进行随机效应荟萃分析和定性综合。结果:纳入167,107例的13项研究的证据表明,二甲双胍使用者的髋关节/膝关节OA发生率降低33%(合并风险比(rr) 0.67, 95%可信区间(CI) 0.61至0.74)。定性综合表明,磁共振成像评估的内侧软骨损失减少,二甲双胍使用者在疼痛、关节功能和生活质量方面的症状进展延迟。至关重要的是,二甲双胍与JA风险降低43%相关(合并RR 0.57, 95% CI: 0.38至0.84),与单独患有糖尿病/肥胖的患者相比,先前存在OA的患者(RR 0.37对0.81)和接受两年以上治疗的患者(RR 0.38对0.80)具有增强的保护作用。结论:二甲双胍可降低髋关节/膝关节OA发病率,减缓影像学/症状进展。它显著降低了JA的风险,特别是对于已经存在OA并接受长期二甲双胍治疗的患者。这些发现支持在该亚组中考虑二甲双胍,同时强调需要进行试验以确认其对糖尿病/肥胖但未确诊OA的患者的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Arthroplasty
Journal of Arthroplasty 医学-整形外科
CiteScore
7.00
自引率
20.00%
发文量
734
审稿时长
48 days
期刊介绍: The Journal of Arthroplasty brings together the clinical and scientific foundations for joint replacement. This peer-reviewed journal publishes original research and manuscripts of the highest quality from all areas relating to joint replacement or the treatment of its complications, including those dealing with clinical series and experience, prosthetic design, biomechanics, biomaterials, metallurgy, biologic response to arthroplasty materials in vivo and in vitro.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信